Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study

• Κύριοι συγγραφείς: Calogera Butera (Συγγραφέας), Ilaria Cetta (Συγγραφέας), Roberta Messina (Συγγραφέας), Laura Zanandrea (Συγγραφέας), Roberto Santangelo (Συγγραφέας), Bruno Colombo (Συγγραφέας), Massimo Filippi (Συγγραφέας), Ubaldo Del Carro (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: SAGE Publishing, 2024-10-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Since the high burden of chronic migraine (CM), it is challenging to identify the best prevention treatment. Based on the preclinical evidence about the different therapeutic targets of onabotulinumtoxinA (BT-A), acting on C-fibers, and anti-CGRP monoclonal antibodies (mAbs), acting on Aδ-fibers, th...